Morimatsu LifeSciences

What Morimatsu LifeSciences does

Morimatsu LifeSciences is a business segment of Hong Kong-listed Morimatsu International Holdings Limited (HKEX: 2155.HK) that designs, manufactures, and delivers modular process systems and integrated facilities for the pharmaceutical and biopharmaceutical industries. Its offering spans upstream bioprocess equipment (including a 500L bioreactor and the newly acquired Bioengineering AG stirred-tank platform), downstream processing, fill-finish systems (notably a Vial Filling Line), and a growing portfolio of digital intelligence products such as the Mo-DTS digital twin, Mo-OES predictive maintenance, Mo-PES multimodal AI, and a manufacturing execution system with anomaly detection. The group serves pharmaceutical manufacturers, biopharmaceutical companies, fast-moving consumer goods producers, medical aesthetics firms, and data-center operators, with 14 offices across China, Japan, India, Singapore, Sweden, Switzerland, Italy, USA, and Mexico, and a project footprint covering more than 40 countries; manufacturing bases are located in Shanghai, Nantong, Wuhan, Changshu, and Mexico. Legacy capabilities include 90 completed modular production facilities delivered by subsidiary Pharmadule Morimatsu AB (Sweden, founded 1986, integrated 2011) and more than 300 engineering design and validation solutions developed across the platform.

The business model is project-based capital equipment sales of modular facilities and process skids, complemented by engineering, qualification, validation, and lifecycle services; the 2026 launch wave and the Mo-EAMaster Phase II partnership with Zencore Biologics indicate a deliberate shift toward recurring digital and platform revenues layered on top of the installed base. Customers operate under stringent regulatory regimes — FDA, cGMP, EU GMP, NMPA GMP, WHO, PIC/S, GAMP5, and 21 CFR Part 11 — and the company has secured external sustainability credentials including EcoVadis Silver Medal (top 6%), CDP B rating, and SBTi-validated emission targets, which are increasingly material in multinational pharma procurement. The 2026 acquisition of Bioengineering AG adds Swiss upstream bioreactor expertise, rounding out an end-to-end stack from cell culture through fill-finish and digital operations.

Name

Morimatsu LifeSciences

Legal name

Shanghai Morimatsu Pharmaceutical Equipment Engineering Co., Ltd.

Website

https://morimatsu-lifesciences.com

Company type

Public

Operating status

Operating

Headcount range

51–100 employees

Short description

Morimatsu LifeSciences, a segment of Morimatsu International Holdings (HKEX: 2155.HK), designs and delivers modular process systems and integrated facilities for pharmaceutical and biopharmaceutical manufacturers across 40+ countries through 14 offices and five manufacturing bases.

Ownership category

akta.pro rank

Product category

Pharmaceutical & Biopharmaceutical Process Equipment

NAICS

Analytical Laboratory Instrument Manufacturing (334516)

SIC

Laboratory Analytical Instruments (3826)

akta.pro primary industry

Aseptic Processing, Fill-Finish & Sterile Manufacturing Tech (isolators, lyophilization interfaces) (HLAAAJAG)

akta.pro secondary industry

Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES) (HLAAAJAE)

Keywords

• Pharmaceutical process equipment
• Biopharmaceutical manufacturing systems
• Modular facility solutions
• Bioreactor systems
• Single-use bioprocessing

Headquarters

HQ city

Stockholm

HQ country

Sweden

HQ region

Europe

Offices14 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Core Equipment Sales: Sale of core pharmaceutical and biopharmaceutical equipment including bioreactors, TFF filtration systems, inline conditioning systems, chromatography systems, wave bioreactors, and single-use solutions (bioreactors, mixers, storage systems, bags).
2. Process Systems: Complete process system solutions including bioprocessing systems, preparation systems, chemical API systems, and fast-moving consumer product mixing systems.
3. Modular Facility Solutions: Pharmadule Morimatsu modular plant solutions providing turnkey factory facilities from design to validation. Off-site modular construction reduces on-site construction time and enables rapid product launches.
4. Automation Systems: PLC/DCS system solutions, SCADA systems, and weighing management systems using platforms including Siemens TIA/PCS7, Rockwell Studio5000/FactoryTalk, and Emerson DeltaV.
5. Digital-Intelligent Plant Solutions: Digital twin, smart operations, AI solutions, and MES systems for pharmaceutical manufacturing digitalization.
6. Professional Services: Process design, engineering design, digital operations, validation services, and maintenance support throughout the equipment and facility lifecycle.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels12 records

Core offering

Morimatsu LifeSciences designs, manufactures, and integrates pharmaceutical and biopharmaceutical process equipment (bioreactors, TFF filtration, mixing systems, single-use solutions), turnkey modular facilities (Pharmadule), and digital-intelligent plant platforms (MES, digital twin, smart operations, AI). The company delivers end-to-end solutions from process design and engineering through validation and lifecycle support, serving drug manufacturers across upstream cultivation, downstream purification, formulation, and sterile filling.

Product overview

Morimatsu LifeSciences offers a comprehensive portfolio of core equipment, process systems, and digital-intelligent plant solutions for pharmaceutical, biopharmaceutical, medical aesthetics, and fast-moving consumer goods (FMCG) industries. The product portfolio includes: Process Systems (Bioprocessing System, Preparation System, Chemical API System, Fast Moving Consumer Product Mixing System); Modular Facilities from Pharmadule Morimatsu for turnkey pharmaceutical plant deployment; Core Equipment including Bioreactors, TFF Filtration Systems, Inline Conditioning Systems, Wet Granulators, and Fluidized Beds; Laboratory One-stop Solutions with benchtop/wave bioreactors and chromatography systems; Single-use Solutions including bioreactors, mixers, and storage systems; and Non-standard Equipment (Vessels, Heat Exchangers, Utility Panels). Digital platforms include MES System Solution, Mo-EAMaster (EAM), Mo-DTS (Digital Twin), Mo-OES (Smart Operations), Mo-PES (AI), Mo-DRS (Automation), Weighing Management System, PUPSIT Integrated Solution, and BCS Sterile Automatic Sampling System. The portfolio also includes Bioengineering AG products (Taberis bioreactors, Ondalis, Bagento single-use bioreactors) acquired by Morimatsu Group. Services span Process Design, Engineering Design, Digital Operation, Validation, Modular Solutions, and Automation Design. The company operates global manufacturing facilities in Sweden, Switzerland, Italy, US, India, Singapore, China, and Japan.

Differentiator

Problem solved

Functional benefit

Brands

• Pharmadule Morimatsu: Modular plant and solutions provider for pharmaceutical and biopharmaceutical manufacturing facilities, established 1986, completed 90 production facilities and over 300 engineering design and validation solutions
• Bioengineering AG (BioE)
• 瑞典森松法玛度
• MoriSora Technology

Products and services

• Process System
• Modular Facility
• Core Equipment (Bioreactor, TFF Filtration, Inline Conditioning, Multifunctional Filter, Wet Granulator, Fluidized Bed)
• Laboratory One-stop Solution
• Single-use Solution
• Non-standard Equipment (Vessels, Heat Exchangers, Utility Panels)
• Vial Filling Line
• Digital-Intelligent Weighing Management System
• MES System Solution
• Mo-DTS Digital Twin Solutions
• Mo-OES Smart Operations Solutions
• Mo-PES Multimodal AI Solutions
• Mo-DRS Digitalization & Automation Solutions
• BCS Sterile Automatic Sampling System
• PUPSIT Integrated Solution
• Mo-EAMaster
• 500L Stainless Steel Bioreactor
• 500L Media Preparation System and 1,000L Feeding System
• Bagento Single-use Bioreactor
• Taberis and Ondalis Bioreactor Systems (Bioengineering AG)
• Process Design Service
• Engineering Design Service
• Digital Operation Service
• Validation Service
• Modular Solution Service
• Automation Design Service

Quantifiable outcome

• Cell culture fermentation cycle maintained at 21 hours with cell density (OD600) consistently around 60 for plasmid DNA production
• +4 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability13 records

Feature8 records

Partnerships

Two partnerships are on record, tiered core.

• Zencore BiologicscoreStrategic or Co-development Partner · 9 January 2026Mo-EAMaster Phase II collaboration for digital intelligence upgrades in pharmaceutical asset management. Phase I established equipment records digitization, standardized maintenance, and end-to-end lifecycle digitalization with improved OEE. Phase II targets enhanced maintenance, calibration, inspection, and spare parts modules with well-defined milestones including requirements analysis, functional development, CSV validation, and final acceptance.
• Pharmadule Morimatsu ABcoreOthers · 1 January 2011Pharmadule became a member of Morimatsu Group in 2011, integrating modular plants with process systems. Since 1986, Pharmadule has completed 90 production facilities and 300+ engineering design and validation solutions. The partnership enables higher-quality and faster turnkey solutions for pharmaceutical and biopharmaceutical clients.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• IMA Group: Italian-based manufacturer of automated processing and packaging machines for the pharmaceutical industry, including aseptic fill-finish, solid dose, and sterile manufacturing equipment. Overlaps with Morimatsu's fill-finish, granulation, and aseptic processing product lines.
• GEA Group: Engineering group supplying process technology, components, and turnkey plants for the pharmaceutical and biopharmaceutical industries. Competes with Morimatsu's process systems and modular facility offerings, particularly in liquid processing and aseptic manufacturing.
• Syntegon Technology (formerly Bosch Packaging Technology): Processing and packaging technology supplier for the pharmaceutical industry, including fill-finish, lyophilization, and sterile manufacturing systems. Directly competes with Morimatsu's Vial Filling Line and aseptic processing equipment.
• G-CON Manufacturing: US-based manufacturer of prefabricated, modular cleanroom solutions for pharmaceutical and biopharmaceutical manufacturing. Directly competes with Pharmadule Morimatsu's modular facility business in the off-site construction and rapid-deploy plant segment.
• Merck KGaA (Life Science / MilliporeSigma): Provides bioprocessing equipment, single-use systems, and process solutions for pharma and biopharma manufacturers. Competes with Morimatsu in bioreactor systems, filtration, and process-scale solutions, with particular overlap in biopharma manufacturing services.
• Cytiva (Danaher): Bioprocessing equipment and solutions provider (formerly GE Healthcare Life Sciences) covering bioreactors, chromatography, filtration, and process development. Competes directly with Morimatsu's bioprocessing equipment portfolio across upstream and downstream operations.
• Sartorius AG: Global leader in bioprocessing equipment, bioreactors, and single-use solutions for the biopharmaceutical industry. Directly competes with Morimatsu's bioreactor and single-use product lines, especially in upstream bioprocessing where Sartorius has deeper installed-base and consumables lock-in.
• Tofflon Science & Technology: Chinese pharmaceutical equipment manufacturer offering bioreactors, fermentation systems, lyophilization, fill-finish, and process systems. The closest direct China-based peer to Morimatsu LifeSciences, with overlapping bioprocessing and pharma equipment product portfolios.

Broad incumbents

• Thermo Fisher Scientific: Diversified life-sciences and pharma services conglomerate offering bioproduction equipment, CDMO services, and process analytics. Significantly larger and broader than Morimatsu, with overlapping bioproduction equipment and integrated process solutions.

Regional players

• Shanghai Biaozhi Purification Engineering: Chinese engineering firm specializing in cleanrooms, modular pharmaceutical facilities, and aseptic processing environments. Regional competitor in the China market for integrated modular facility solutions competing with Pharmadule Morimatsu.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCENxoLXPnsz9c7otvBIl5Pg
• LinkedInlinkedin.com/company/morimatsu-lifesciences

Compliance17 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Morimatsu LifeSciences